Boston Scientific Co. (NYSE:BSX) SVP Wendy Carruthers sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, November 2nd. The stock was sold at an average price of $36.64, for a total value of $54,960.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of NYSE:BSX opened at $38.44 on Friday. The company has a market capitalization of $50.99 billion, a price-to-earnings ratio of 30.51, a PEG ratio of 2.42 and a beta of 0.68. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.56 and a current ratio of 0.78. Boston Scientific Co. has a 52-week low of $24.54 and a 52-week high of $39.44.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 24th. The medical equipment provider reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.01. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.40 billion. Boston Scientific had a return on equity of 26.44% and a net margin of 6.93%. The company’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.31 earnings per share. Equities research analysts anticipate that Boston Scientific Co. will post 1.39 earnings per share for the current year.
BSX has been the subject of several recent analyst reports. Morgan Stanley raised their target price on Boston Scientific from $33.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, July 26th. Argus raised their target price on Boston Scientific from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Friday, October 26th. Piper Jaffray Companies raised their target price on Boston Scientific to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, July 26th. Jefferies Financial Group reaffirmed a “hold” rating and set a $34.00 target price on shares of Boston Scientific in a research note on Thursday, July 26th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $37.00 target price on shares of Boston Scientific in a research note on Thursday, July 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Boston Scientific presently has a consensus rating of “Buy” and an average price target of $39.00.
ILLEGAL ACTIVITY NOTICE: “Boston Scientific Co. (BSX) SVP Wendy Carruthers Sells 1,500 Shares” was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.wkrb13.com/2018/11/10/boston-scientific-co-bsx-svp-wendy-carruthers-sells-1500-shares.html.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Story: How accurate is the Rule of 72?
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.